Dallas-based Children’s Health and Irving-based Toyota Motor North America have completed a strategic initiative to reduce rates of central line-associated blood stream infections (CLABSIs) in Children’s Health gastroenterology units. The partnership, which began in June of 2016, has implemented and created several initiatives to “improve patient safety and quality of care.”
According to Children’s Health, the initiative reduced rates of CLABSIs by 75 percent. CLABSIs occur when bacteria or germs enter the blood through a central line tube, usually placed in a large vein that routes to the heart. These serious infections affect around 250,000 nationally and cost $6 billion to treat.
The teams worked together to identify instances that cause CLABSIs, concluding “the immediate environment of care is vital in the process of maintaining cleanliness of the central line.” After implementing practices to have a sterile, clean environment, it was found that the procedures helped reduce CLABSIs.
To further improve gastroenterology practices, Children’s Health will “roll out improved practices from the collaboration system-wide, ultimately empowering team members to implement improved care processes to prevent infections across multiple hospital units” by the end of this year.
Dr. Rustin Morse, vice president and chief quality officer at Children’s Health, said in a statement: “Patients and their families place a sacred trust in us to take care of their children and make them well. While there will always be risks associated with specialized treatment in hospital settings, we are grateful for the expertise of [the Toyota Production System Support Center]. Its team of the finest process improvement experts in the world helped us minimize those risks. We are also tremendously proud of our clinical team members for their commitment to excellence in patient safety.”